<DOC>
	<DOCNO>NCT02754635</DOCNO>
	<brief_summary>Induction labor term versus expectant management among woman abnormal maternal biochemical marker . A randomized control trial</brief_summary>
	<brief_title>Induction Versus Expectant Management With Abnormal Maternal Biochemical Markers</brief_title>
	<detailed_description>Pregnancy-associated plasma protein A ( PAPP-A ) , alpha-fetoprotein ( AFP ) , human chorionic gonadotropin ( hCG ) , inhibin A , biochemical marker part first second trimester screen test , Down syndrome neural tube defect pregnancy . These biochemical marker show also associate slightly increase risk adverse pregnancy outcome absence aneuploidy neural tube defect , example ; preeclampsia , low birth weight , placental abruption , preterm labor , intrauterine fetal death . There guideline regard management case assume reassure maternal fetal status normal , term ( 38 - 39 week ) . However , adverse event may still develop 38 42 week calculate accord ongoing pregnancy . Investigators aim randomize trial examine effect induction labor 38 - 39 week compare expectant management among woman abnormal first second biochemical screening test maternal perinatal outcome . Enrollment : 320 woman group . Interim analyse perform enrol 50 % participant .</detailed_description>
	<criteria>HCG , AFP Inhibin great 2 multiple median ( MOM ) PAPPA le 0.15 MOM . Singleton . Appropriate gestational age fetus . Reassuring fetal status include normal amniotic fluid index . Any hypertensive disorder . Indication induction labour enrollment . Any contraindication induction labour . Prior cesarean delivery . Any contraindication trial vaginal delivery .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Abnormal first second trimester biochemical marker</keyword>
	<keyword>maternal perinatal morbidity/mortality</keyword>
</DOC>